Optimizing the therapeutic efficacy of cisplatin PEGylated liposomes via incorporation of different DPPG ratios: In vitro and in vivo studies

Colloids and Surfaces B: Biointerfaces

Volumn 136, Issue , 2015, Pages 885-891

  Marzban, Ehsan ^a   Alavizadeh, Seyedeh Hoda ^b   Ghiadi, Maral ^b   Khoshangosht, Mostafa ^b   Khashyarmanesha, Zahra ^c   Abbasi, Azam ^b   Jaafari, Mahmoud R ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

C26 colon carcinoma; Cisplatin; DPPG; Fusogenic property; PEGylated liposome

Indexed keywords

LIPID BILAYERS; LIPOSOMES; MOTION PICTURE EXPERTS GROUP STANDARDS; PHOSPHOLIPIDS; TUMORS;

CIS-PLATIN; COLON CARCINOMA; DPPG; FUSOGENIC PROPERTY; PEGYLATED LIPOSOMES;

PLATINUM COMPOUNDS;

1,2 DIPALMITOYL SN GLYCERO 3 PHOSPHATIDYLGLYCEROL; CISPLATIN; LIPOSOME; MACROGOL 2000; PHOSPHATIDYLGLYCEROL; UNCLASSIFIED DRUG; 1,2-DIPALMITOYLPHOSPHATIDYLGLYCEROL; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CARCINOMA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG STABILITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIPID BILAYER; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; FEMALE; IN VITRO TECHNIQUES; LIPOSOMES; MICE; MICE, INBRED BALB C; PHOSPHATIDYLGLYCEROLS; POLYETHYLENE GLYCOLS;

EID: 84946557423     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2015.10.046     Document Type: Article

References (29)

1. Pinzani V., Bressolle F., Johanne Haug I., Galtier M., Blayac J.P., Balmès P. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother. Pharmacol. 1994, 35:1-9.
2. Vekris A., Meynard D., Haaz M., Bayssas M., Bonnet J., Robert J. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res. 2004, 64:356-362.
3. Boulikas T., Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol. Rep. 2004, 11:559-595.
4. Steichen S., Caldorera-Moore M., Peppas N. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur. J. Pharm. Sci. 2012, 48:416.
5. Weiss R., Christian M. New cisplatin analogues in development. A review. Drugs 1993, 46:360-377.
6. Allen T., Cullis P. Drug delivery systems: entering the mainstream. Science (New York, NY) 2004, 303:1818-1822.
7. Lasic D., Papahadjopoulos D. Liposomes revisited. Science (New York, NY) 1995, 267:1275-1276.
8. Maeda H., Nakamura H., Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug. Deliv. Rev. 2013, 65:71-79.
9. Meerum T.J., Groenewegen G., Pluim D., Maliepaard M., Tibben M., Huisman A., ten Bokkel H.W., Schot M., Welbank H., Voest.Phase E., pharmacokinetic study of SPI-77 A liposomal encapsulated dosage form of cisplatin. Cancer Chemother. Pharmacol. 2002, 49:201-210.
10. Boulikas T. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin. Investig. Drugs 2009, 18:1197-1218.
11. Boulikas T. Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin. Lipoplatin as a chemotherapy and antiangiogenesis drug. Cancer. Ther. 2007, 5:351-376.
12. Cheng C., Debefve E., Haouala A., Andrejevic-Blant S., Krueger T., Ballini J., Peters S., Decosterd L., van den Bergh H., Wagnieres G. Photodynamic therapy selectively enhances liposomal doxorubicin uptake in sarcoma tumors to rodent lungs. Lasers Surg. Med. 2010, 42:391.
13. Newman M., Colbern G., Working P., Engbers C., Amantea M. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 1998, 43:1-7.
14. Zisman N., Dos Santos N., Johnstone S., Tsang A., Bermudes D., Mayer L., Tardi P. Optimizing Liposomal cisplatin efficacy through membrane composition manipulations. Chemother. Res. Pract. 2010, 2011:213848.
15. Meerum T.J., Tibben M., Welbank H., Schellens J., Beijnen J. Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry. Fresenius J. Anal. Chem. 2000, 366:298-302.
16. Huang Z., Jaafari M.R., Szoka F.C. Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery. Angew. Chem. 2009, 121:4210-4213.
17. Huang Z., Szoka F. Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties. J. Am. Chem. Soc. 2008, 130:15702-15712.
18. Amin M., Badiee A., Jaafari M. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Int. J. Pharm. 2013, 458:324-333.
19. Schluep T., Hwang J., Cheng J., Heidel J., Bartlett D., Hollister B., Davis M. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res. 2006, 12:1606-1614.
20. Alavizadeh S.H., Badiee A., Golmohammadzadeh S., Jaafari M.R. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma. Int. J. Pharm. 2014, 473:326-333.
21. Washington C. Stability of lipid emulsions for drug delivery. Adv. Drug. Deliv. Rev. 1996, 20:131-145.
22. Allen C., Dos Santos N., Gallagher R., Chiu G., Shu Y., Li W., Johnstone S., Janoff A., Mayer L., Webb M. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci. Rep. 2002, 22:225-250.
23. Gabizon A.A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992, 52:891-896.
24. Ross M., Krol S., Janshoff A., Galla H. Kinetics of phospholipid insertion into monolayers containing the lung surfactant proteins SP-B or SP-C. Eur. Biophys. J. 2002, 31:52-61.
25. Jacobson K., Papahadjopoulos D. Phase transitions and phase separations in phospholipid membranes induced by changes in temperature, pH, and concentration of bivalent cations. Biochemistry 1975, 14:152-161.
26. Kirjavainen M., Urtti A., Jääskeläinen I., Suhonen T., Paronen P., Valjakka-Koskela R., Kiesvaara J., Mönkkönen J. Interaction of liposomes with human skin in vitro-the influence of lipid composition and structure. Biochim. Biophys. Acta 1996, 1304:179-189.
27. Stark B., Pabst G., Prassl R. Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: effects of cryoprotectants on structure. Eur. J. Pharm. Sci. 2010, 41:546-555.
28. Papahadjopoulos D., Moscarello M., Eylar E., Isac T. Effects of proteins on thermotropic phase transitions of phospholipid membranes. Biochim. Biophys. Acta 1975, 401:317-335.
29. Stathopoulos G. Liposomal cisplatin: a new cisplatin formulation. Anticancer drugs 2010, 21:732-736.